ENTA will likely seek to develop a combination regimen of oral DAAs for SARS-CoV-2, but they haven’t committed to that, as far as I know. (ENTA has committed to developing an all-oral combination regimen for HBV.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”